Synonyms: VX-121 | VX121
vanzacaftor is an approved drug
Compound class:
Synthetic organic
Comment: Vanzacaftor (VX-121) is a cystic fibrosis transmembrane regulator (CFTR) protein modulator/corrector for class II CFTR mutations (the most common being F508del). The principal action of vanzacaftor is to restore the folding/trafficking of mutated CFTR to the plasma membrane. VX-121 also stimulates a K+ secretory current that is mediated by the large-conductance calcium-activated potassium channel (BKCa, KCa1.1) [2].
|
|
References |
1. Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M et al.. (2025)
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med, 13 (3): 256-271. [PMID:39756424] |
2. Kolski-Andreaco A, Taiclet S, Myerburg MM, Sembrat J, Bridges RJ, Straub AC, Wills ZP, Butterworth MB, Devor DC. (2024)
Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121. J Clin Invest, 134 (16). [PMID:38954478] |